alexa The Effect Of Hippocampal And/or Striatal Injection Of α-synuclein Fibrils On Novel Object And Novel Place Recognition
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Summit on Clinical Pharmacy
December 02-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

David A Johnson
Keynote: Clinic Pharmacol Biopharm
DOI: 10.4172/2167-065X.S1.005
Neurodegenerative disorders are commonly associated with disruptions in motor and/or cognitive functions. Dementia is a common symptom of Parkinson disease and cellular accumulations of α-synuclein are a histological hallmark of that disorder. There are many animal models of Parkinson disease that utilize neurotoxins to destroy dopaminergic neurons that result in cognitive impairment but do not necessarily display α-synuclein accumulation. There are also transgenic models that broadly express human α-synuclein with resulting cognitive impairments. However, the differential effect of α-synuclein fibrils in specific brain structures on cognitive functions in rats has not been elucidated. In a pilot study, male Sprague-Dawley rats were injected bilaterally in the hippocampus and/or dorsal striatum with α-synuclein fibrils. Four to seven months later the animals were tested for cognitive function using novel object and novel place recognition paradigms. The results demonstrated a significant impairment of novel object recognition but not place recognition in rats injected in the dorsal striatum (P=0.01) and a trend toward impairment of novel place recognition but not object recognition in animals injected in the hippocampus (P=0.06). The results suggest that specific cognitive impairments in Parkinson disease may be related to the relative distribution of α-synuclein in cortical structures.

David A Johnson is currently Professor of Pharmacology and Toxicology and the Division Head of Pharmaceutical Sciences of the Mylan School of Pharmacy and Graduate School of Pharmaceutical Sciences at Duquesne University, Pennsylvania. He received his PhD from the Massachusetts College of Pharmacy and Allied Health Sciences in 1990 majoring in Pharmacology with a minor in Neuroscience. Following the award of his degree, he was a Post-doctoral fellow in the laboratories of Dr. Bernard Lown at the Harvard School of Public Health and Dr. Richard J Wurtman at Interneuron Pharmaceuticals. His primary scholarly interests include cholinergic function in learning, memory and attention. He has authored over 50 publications in various areas of pharmacology, several book chapters and two patents. Most recently, he directed a clinical trial of the cognitive enhancing effects of an acetylcholine precursor and excitatory neuromodulators

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version